NCT02051894View on ClinicalTrials.gov

NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encephalopathy

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Circulatory Failure
Interventions
DRUG

Dobutamine

"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."

Trial Locations (1)

BN2 5BE

Trevor Mann Baby Unit, Brighton

All Listed Sponsors
collaborator

European Union

OTHER

lead

Brighton and Sussex University Hospitals NHS Trust

OTHER

NCT02051894 - NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encephalopathy | Biotech Hunter | Biotech Hunter